A new research center of national significance was opened in Budapest on Monday, led by Balázs Rózsa, the founder of Femtonics, Roska Botond, whose therapy partially restored the vision of a completely blind man a few months ago. The BrainVision Center is responsible for preparing basic research for the diagnosis and therapy of central nervous system diseases and for implementing a basic research program for vision restoration, but it also provides opportunities to develop optical systems based on process light and brain interaction, MTI writes.

At the founding ceremony of the research center on Monday, Minister of Innovation and Technology László Palkovics talks about the need to place innovation results in an international environment, and the government will examine the areas of research that are important at the international level. He mentioned the ELI center in Szeged and the MIT Catalyst program as examples, but emphasized that Roska Botond’s research also falls into this category. As he said, they wanted to achieve the project by supporting that

The Hungarian researcher working in the restoration of vision, living in Switzerland, should continue his work in Hungary, the background of which was established with the current institute, and he added that he would be very successful in bringing Roska Botond’s research to Hungary.

Roska, head of the Basel Institute for Molecular and Clinical Ophthalmology (IOB) and a visiting professor at Semmelweis University, has become internationally known for her achievements in vision recovery therapy. In short, the essence of highly optogenetic therapy is to take a gene from algae, bacteria and microbes that encodes a sensitive protein and then incorporate it into one of the cells of the retina by gene therapy, which will make it sensitive. Therapy has been used successfully in five patients so far, but there is still a long way to go to involve more people in the therapy and not only detect objects as a result of the treatment. After the breakthrough in May, Telex also talked to Roska Botond about the significance, background and optogenetic therapy of the study, an idea they can read.

Another Monday, Balázs Rózsa, founder of Femtonics and the new research institute, said that work at the BrainVision Center using new molecular biology methodologies and 3D laser microscopy technology would reveal more effective optogenetic response such as depression, dementia or epilepsy. He also said they want to use microscope technology at the center that combines the benefits of two- and three-dimensional techniques in a single device.

The new type of procedure allows cells in the brain that are labeled with different genetic methods to be examined in motion to examine how effectively different vision-restoring genetic therapies have restored retinal function. With this, and with Roska Botond’s new biological biological methodological tools and the human tissue cultures of the Institute for Anatomy, Histology and Development at Semmelweis University, you will be able to choose the most effective therapeutic options. According to Rózsa, the cooperation will result in the creation of one of the most important human translation centers in the world, when it is scheduled to start operating in December.